Eagle Bay Advisors’s Regenxbio RGNX Stock Holding History

Eagle Bay Advisors’s Portfolio RGNX Stock Details RGNX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-290	Closed	-$9K	–	818
2021 Q4	$9K	Buy	+290	New	+$9.88K	0.01%	708

Other funds holding RGNX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

ACM

Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

First Manhattan New York $39.2B AUM 21.04% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Eagle Bay Advisors's RGNX Position: Q1 2022 in Review

Eagle Bay Advisors sold out of Regenxbio (RGNX) in Q1 2022, closing a stake of 290 shares — an estimated $9K sold.

Eagle Bay Advisors first reported a position in RGNX in Q4 2021 and held it in 1 quarter. The position peaked at $9K in Q4 2021. 188 funds tracked by Wall St. Rank hold RGNX as of Q1 2022.

Eagle Bay Advisors reported no remaining Regenxbio position as of Q1 2022 after selling out during the quarter.
Eagle Bay Advisors sold 290 Regenxbio shares in Q1 2022, an estimated $9K.
Eagle Bay Advisors first reported a position in Regenxbio in Q4 2021 and held it in 1 quarter.
Eagle Bay Advisors's Regenxbio position peaked at $9K in Q4 2021.
188 funds tracked by Wall St. Rank held Regenxbio as of Q1 2022.

Based on Eagle Bay Advisors's 13F filing for Q1 2022, filed 11 May 2022.